Flag International Outside United States
intl/data image

Macroplastique ® Clinical Data

Widely used for more than 15 years with excellent clinical results, Macroplastique is a closely studied product with more than 50 articles pertaining to its safety and effectiveness in treating stress urinary incontinence (SUI) in men and women as well as vesicoureteral reflux (VUR) in children.

Abstracts are listed by publication year with the most recent listed first. 

Click on the article title to view the full abstract:

Search clinical data abstracts:

 
Display clinical data pertaining to the treatment of:
 
Short and long term durability outcomes for female stress urinary incontinence: a systematic review and meta analysis of polydimethylsiloxane injection
Ghoniem, G., Miller, C. (2012). Poster, Society for Urodynamics and Female Urology (SUFU) annual meeting, New Orleans, LA.
Effect of the Macroplastique Implantation System for stress urinary incontinence in women with or without a history of an anti-incontinence operation.
Gumus I.I., Kaygusuz, I., Derbent, A., Simavli, S., & Kafali, H. (2011). International Urogynecological Journal, 22(6):743-749.
Effect of the Macroplastique Implantation System for stress urinary incontinence in women with or without a history of an anti-incontinence operation.
Gumus I.I., Kaygusuz, I., Derbent, A., Simavli, S., Kafali, H. (2011) International Urogynecological Journal, Online First 4/2/11
Review and analysis methodology of three pivotal urethral bulking agent trials: are the analyses treated equal?
Ghoniem, G. (2010). Poster, International Continence Society, Toronto, Canada.
Durability of Macroplastique® injection for female stress urinary incontinence: two years experience.
Corcos, J., et al. (2010). Poster, Society for Urodynamics and Female Urology, St. Petersburg, FL.
Urethral bulking agents used in the United States: how are they analyzed?
Ghoniem, G. et al. (2010). Poster, Society for Urodynamics and Female Urology, St. Petersburg, FL.
Improved outcomes in patients with transient urinary retention after Macroplastique urethral bulking procedure.
Williams, E. et al. (2010). Poster, Society for Urodynamics and Female Urology, St. Petersburg, FL.
Long term durability of polydimethylsiloxane injectable bulking agent (Macroplastique®) in urethral tissues: animal study histopathology.
Wustenberg, W. (2010). Poster, Society for Urodynamics and Female Urology, St. Petersburg, FL.
Redefining the success rate of bulking agents: Role of composite endpoints.
Renganathan, A., et al. (2009). Poster, International Continence Society, San Francisco, CA.
A cost effective approach to the mid-urethra: An economic analysis of the use of bulking agents and mid-urethral tapes.
Robinson, D., et al. (2009). Poster, International Urogynecological Association, Como, Italy.
Patient-perceived outcomes in the treatment of stress urinary incontinence: Focus on urethral injection therapy.
Chapple, C., et al. (2007). Int Urogynecol J Pelvic Floor Dysfunct, 18(2), 199-205.
Urethral Macroplastique injection as a treatment for female stress incontinence.
Sander, P., et al. (2004). Ugeskr Læger, 166, 3100-3102.
Long-term efficacy of submucosal urethral injection for genuine stress incontinence in women.
Zafirakis, H.G., Nathan, S., & Shah, J. (2002).AUA abstract, Florida, USA.
The treatment of sphincter incontinence with periurethral silicone implants (Macroplastique).
Peeker, R., et al. (2002). Scand J Urol Nephrol, 36(3), 194-198.
 

MORE CLINICAL DATA

Urgent PC
Urgent® PC

Macroplastique
Macroplastique

 

 

PTQ Implants

 

 

Vox implants